argenx SE (ARGX) PT Raised to $707 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
argenx SE (ARGX) PT Raised to $675 at Oppenheimer
November 21, 2024 5:08 AM ESTOppenheimer analyst Leland Gershell raised the price target on argenx SE (NASDAQ: ARGX) to $675.00 (from $646.00) while maintaining a Outperform rating.
The analyst comments "Yesterday ARGX announced clinical proof-of-concept in myositis, with subQ efgart yielding statistically-significant improvement across all three myositis subtypes being evaluated in... More
argenx SE (ARGX:BB) (ARGX) PT Raised to EUR670 at Barclays
November 21, 2024 1:34 AM ESTBarclays analyst Charles Pitman-King raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR670.00 (from EUR650.00) while maintaining a Overweight rating.
The analyst comments: "Following the positive GO decision from the P2 analysis of the ongoing P2/3 ALKIVIA trial, noting... More
argenx SE (ARGX) PT Raised to $706 at Evercore ISI
November 20, 2024 3:57 PM ESTEvercore ISI analyst Gavin Clark-Gartner raised the price target on argenx SE (NASDAQ: ARGX) to $706.00 (from $675.00) while maintaining a Outperform rating.
... MoreLate Morning $5 Dip in argenx SE (ARGX) Attributed to Raymond James Comments, 'we are introducing the myositis opportunity into our model'
November 20, 2024 11:44 AM ESTRaymond James analyst Danielle Brill raised the price target on argenx SE (NASDAQ: ARGX) to $770.00 (from $688.00) while maintaining a Strong Buy rating.
The analyst comments "This morning, ARGX announced their plans to advance development of efgartigimod (SC) into Phase 3 for myositis. The Go decision... More
